Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air Inc is experiencing significant growth, as evidenced by a 105% increase in fiscal 3Q26 revenue to $2.2 million and the successful expansion of its international distribution footprint to 40 countries. The company's innovative Nitric Oxide Generator and Delivery System has demonstrated strong market traction, underscored by its first sales to a VA Medical Center, which could enhance its platform credibility. Furthermore, the encouraging preliminary data from the Phase 1 trials of its UNO therapy suggests potential for a differentiated immunotherapeutic approach and reinforces investor confidence in the company’s growth trajectory within the respiratory and oncology sectors.

Bears say

Beyond Air Inc. is repositioning its UNO system from being viewed as a standalone ablation device to an adjunctive immunotherapy tool, indicating a shift in strategic focus that may complicate its marketing and adoption potential. This change suggests potential challenges in gaining regulatory approval and achieving commercial success, particularly in the competitive landscape of immunotherapy. Additionally, the company's dependence on successful integration with existing treatments, such as anti-PD-1 therapy, raises concerns about its long-term revenue prospects and market viability.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.